High blood pressure is often described as a silent threat because people can feel perfectly well while damage slowly develops inside their bodies.
Researchers have now tested an experimental treatment that not only lowered blood pressure in mice but also reversed some damage in their arteries and kidneys.
The treatment, called Compound17b or Cmpd17b, works very differently from most medicines currently prescribed for hypertension. It targets part of the body’s response to inflammation rather than focusing mainly on hormones, fluid levels or the usual nerve signals that control blood pressure.
Hypertension develops when the force of blood against artery walls remains too high. Over many years, this extra pressure can make arteries thicker and stiffer and can injure organs that depend on healthy blood vessels.
The heart and kidneys are especially vulnerable. The heart must pump against greater resistance, while the kidneys contain many tiny blood vessels that constantly filter the blood.
Damage to the kidneys can then make blood pressure even harder to control. This creates a cycle in which hypertension harms the kidneys and declining kidney health can contribute to further increases in blood pressure.
Modern blood pressure drugs can interrupt several parts of this cycle. Common treatments relax blood vessels, reduce excess fluid or block chemical signals that cause blood pressure to rise.
Despite these treatments, researchers continue to search for additional causes of hypertension. One area receiving growing attention is chronic inflammation, a continuing immune response that can gradually damage blood vessels and organs.
Inflammation itself is not always bad. It helps the body respond to injury and infection, and a healthy immune response normally includes a later stage in which inflammation settles down and tissue repair begins.
The new research focused on this healing stage. Scientists tested whether Cmpd17b could activate cell receptors involved in controlling and resolving inflammation.
These receptors are found on immune cells and also on cells in the heart and kidneys. Earlier work suggested that Cmpd17b could reduce harmful inflammation and tissue changes after heart injury.
The researchers wanted to know whether it could also help in a type of hypertension caused largely by excessive activity in the body’s automatic nerve system. They used a strain of mice that naturally develops this kind of high blood pressure.
The experiment involved 45 male mice that were 12 weeks old. Some had normal blood pressure and others had hypertension, and each type received either Cmpd17b or an inactive treatment for 28 days.
Blood pressure, heart rate and movement were monitored throughout the experiment. During the final week, the researchers also used ultrasound and examined the heart, kidneys and blood vessels for signs of damage.
Cmpd17b reduced average arterial pressure by about 6 mmHg in the hypertensive mice. It did not significantly lower blood pressure in the normal mice.
That finding attracted attention because a medicine that mainly acts when blood pressure is abnormally high could potentially reduce the risk of lowering it too far. However, researchers do not yet know whether the same pattern would occur in humans.
The blood pressure effect was gradual. It was strongest during the mice’s active period, when their blood pressure naturally rose to its highest levels.
Even more interesting were changes in the organs. High blood pressure can cause collagen and other material to accumulate in tissue, producing stiff scar-like areas known as fibrosis.
The drug reduced kidney scarring and also lowered collagen buildup in the aorta and the left ventricle of the heart. The strongest tissue-repair effects appeared in the kidneys.
The aorta also showed substantial improvement. After treatment, it was about 37% more flexible and its wall was about 22% thinner.
This matters because a healthy aorta expands slightly every time the heart pushes blood into it. A stiff, thickened aorta cannot absorb that pressure as effectively and can contribute to further strain on the heart and blood vessels.
Yet the treatment had clear limits. Although the structure of the large artery improved, Cmpd17b did not fully repair the function of smaller blood vessels.
It also did not significantly improve the heart’s ability to pump blood during the short study. This suggests that different forms of damage caused by hypertension may respond differently to treatment.
The findings are especially interesting because conventional anti-inflammatory drugs are not an easy solution to chronic hypertension. Broadly suppressing inflammation can interfere with the immune system’s ability to fight infections and perform other essential jobs.
Cmpd17b takes a more focused approach by encouraging signals involved in ending inflammation and promoting repair. If this idea proves successful, it could offer a way to influence inflammation without simply switching off immune defenses.
However, there is a large gap between a successful mouse experiment and a new medicine for patients. The study was small, included only male mice and lasted just 28 days.
Human high blood pressure is also extremely varied. Genetics, age, kidney disease, hormones, body weight, diet, medicines and many other factors can contribute, so a treatment effective in one animal model may not work equally well across patients.
The research was published in Communications Biology in 2026. The study adds to evidence that inflammation may be more than a side effect of hypertension and could become a useful treatment target.
The results are promising because the drug affected both blood pressure and physical damage to organs, particularly the kidneys and aorta. At the same time, the lack of improvement in heart pumping and smaller blood vessels shows that the treatment did not reverse hypertension’s effects everywhere.
For now, Cmpd17b should be viewed as an experimental research tool rather than a future prescription that is close to pharmacies. Larger animal studies and human clinical trials will be necessary to establish its safety, effective dose and true value.
The broader lesson may ultimately be more important than this particular drug. If scientists can learn how to help the body end harmful inflammation and repair blood vessels, future hypertension treatment might do more than lower a number on a blood pressure monitor—it might also help heal some of the damage that high pressure has already caused.
Source: Monash University.
